https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-09-14 06:03:432020-09-14 06:03:43Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-08-17 04:02:372020-08-17 04:02:37Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-06-24 04:09:222020-08-18 13:47:33Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-05-19 04:03:292020-08-18 13:48:12Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-05-19 04:02:492020-08-18 13:49:26Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00ksmithhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgksmith2020-04-29 04:02:332020-08-18 13:49:36Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-24 05:00:442020-08-18 13:49:45Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
https://amplyx.com/wp-content/uploads/2019/11/logo.svg00eallisonhttps://amplyx.com/wp-content/uploads/2019/11/logo.svgeallison2019-09-16 11:08:172020-08-18 13:49:53Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients
